Literature DB >> 20351687

Measuring the 50% haemolytic complement (CH50) activity of serum.

Maurizio Costabile1.   

Abstract

The complement system is a group of proteins that when activated lead to target cell lysis and facilitates phagocytosis through opsonisation. Individual complement components can be quantified however this does not provide any information as to the activity of the pathway. The CH50 is a screening assay for the activation of the classical complement pathway (Fig 1) and it is sensitive to the reduction, absence and/or inactivity of any component of the pathway. The CH50 tests the functional capability of serum complement components of the classical pathway to lyse sheep red blood cells (SRBC) pre-coated with rabbit anti-sheep red blood cell antibody (haemolysin). When antibody-coated SRBC are incubated with test serum, the classical pathway of complement is activated and haemolysis results. If a complement component is absent, the CH50 level will be zero; if one or more components of the classical pathway are decreased, the CH50 will be decreased. A fixed volume of optimally sensitised SRBC is added to each serum dilution. After incubation, the mixture is centrifuged and the degree of haemolysis is quantified by measuring the absorbance of the haemoglobin released into the supernatant at 540 nm. The amount of complement activity is determined by examining the capacity of various dilutions of test serum to lyse antibody coated SRBC. This video outlines the experimental steps involved in analysing the level of complement activity of the classical complement pathway.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20351687      PMCID: PMC3168207          DOI: 10.3791/1923

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  33 in total

1.  FHR4-based immunoconjugates direct complement-dependent cytotoxicity and phagocytosis towards HER2-positive cancer cells.

Authors:  Carole Seguin-Devaux; Jean-Marc Plesseria; Charlène Verschueren; Cécile Masquelier; Gilles Iserentant; Marie Fullana; Mihály Józsi; Jacques H M Cohen; Xavier Dervillez
Journal:  Mol Oncol       Date:  2019-09-30       Impact factor: 6.603

2.  Evaluation of neurobehavioral abnormalities and immunotoxicity in response to oral imidacloprid exposure in domestic chickens (Gallus gallus domesticus).

Authors:  Dana Franzen-Klein; Mark Jankowski; Charlotte L Roy; Hoa Nguyen-Phuc; Da Chen; Lorin Neuman-Lee; Patrick Redig; Julia Ponder
Journal:  J Toxicol Environ Health A       Date:  2020-02-05

3.  Interactions Among Sexual Activity, Menstrual Cycle Phase, and Immune Function in Healthy Women.

Authors:  Tierney K Lorenz; Julia R Heiman; Gregory E Demas
Journal:  J Sex Res       Date:  2017-11-21

4.  Efficacy analysis of hydroxychloroquine therapy in systemic lupus erythematosus: a study on disease activity and immunological biomarkers.

Authors:  Seyed Mostafa Monzavi; Aida Alirezaei; Zhaleh Shariati-Sarabi; Jalil Tavakol Afshari; Mahmoud Mahmoudi; Banafsheh Dormanesh; Faezeh Jahandoost; Ali Reza Khoshdel; Ali Etemad Rezaie
Journal:  Inflammopharmacology       Date:  2018-07-10       Impact factor: 4.473

Review 5.  To PEGylate or not to PEGylate: Immunological properties of nanomedicine's most popular component, polyethylene glycol and its alternatives.

Authors:  Da Shi; Damian Beasock; Adam Fessler; Janos Szebeni; Julia Y Ljubimova; Kirill A Afonin; Marina A Dobrovolskaia
Journal:  Adv Drug Deliv Rev       Date:  2021-12-10       Impact factor: 15.470

6.  Inhibition of complement C1s in patients with cold agglutinin disease: lessons learned from a named patient program.

Authors:  Georg Gelbenegger; Christian Schoergenhofer; Ulla Derhaschnig; Nina Buchtele; Christian Sillaber; Michael Fillitz; Thomas M Schenk; Shirley D'Sa; Ronwyn Cartwright; James C Gilbert; Bernd Jilma; Ulrich Jaeger
Journal:  Blood Adv       Date:  2020-03-24

7.  Kingella kingae Surface Polysaccharides Promote Resistance to Human Serum and Virulence in a Juvenile Rat Model.

Authors:  Vanessa L Muñoz; Eric A Porsch; Joseph W St Geme
Journal:  Infect Immun       Date:  2018-05-22       Impact factor: 3.441

8.  Development of a Sensitive Assay to Screen Nanoparticles in vitro for Complement Activation.

Authors:  Nuzhat Maisha; Tobias Coombs; Erin Lavik
Journal:  ACS Biomater Sci Eng       Date:  2020-07-06

9.  A pilot trial of complement inhibition using eculizumab to overcome platelet transfusion refractoriness in human leukocyte antigen allo-immunized patients.

Authors:  Phuong Vo; Enkhtsetseg Purev; Kamille A West; Emily McDuffee; Tatyana Worthy; Lisa Cook; Geri Hawks; Brian Wells; Reem Shalabi; Willy A Flegel; Sharon D Adams; Robert Reger; Georg Aue; Xin Tian; Richard Childs
Journal:  Br J Haematol       Date:  2020-02-21       Impact factor: 8.615

10.  Intracellular sensing of complement C3 activates cell autonomous immunity.

Authors:  Jerry C H Tam; Susanna R Bidgood; William A McEwan; Leo C James
Journal:  Science       Date:  2014-09-04       Impact factor: 47.728

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.